STARK II PHASE III: A Detailed Section-By-Section Analysis of the Long-Awaited “Final” Rule
Client Alert | 11 min read | 10.02.07
The Crowell & Moring Health Care Group is pleased to provide our clients, colleagues, and friends with our legal analysis of the Stark II Phase III Regulations, recently published in the September 5, 2007 Federal Register. These new regulations present both welcome relief and unanticipated future challenges in the manner in which physician financial relationships with DHS entities are structured. Our goal in preparing this analysis was to create a thoughtful, practical, and "user-friendly" Stark Law resource that incorporates references to prior rulemaking as well as to the proposed 2008 Medicare Physician Fee Schedule Rule. We hope you'll agree that we have accomplished this goal. As always, please feel free to contact your regular Crowell & Moring attorney if you have any questions regarding the analysis, which can be accessed by clicking on the image or link below.
www.crowell.com/pdf/expertise/healthcare/StarkLaw_2007.pdf
Insights
Client Alert | 4 min read | 12.04.25
District Court Grants Preliminary Injunction Against Seller of Gray Market Snack Food Products
On November 12, 2025, Judge King in the U.S. District Court for the Western District of Washington granted in part Haldiram India Ltd.’s (“Plaintiff” or “Haldiram”) motion for a preliminary injunction against Punjab Trading, Inc. (“Defendant” or “Punjab Trading”), a seller alleged to be importing and distributing gray market snack food products not authorized for sale in the United States. The court found that Haldiram was likely to succeed on the merits of its trademark infringement claim because the products at issue, which were intended for sale in India, were materially different from the versions intended for sale in the U.S., and for this reason were not genuine products when sold in the U.S. Although the court narrowed certain overbroad provisions in the requested order, it ultimately enjoined Punjab Trading from importing, selling, or assisting others in selling the non-genuine Haldiram products in the U.S. market.
Client Alert | 21 min read | 12.04.25
Highlights: CMS’s Proposed Rule for Medicare Part C & D (CY 2027 NPRM)
Client Alert | 11 min read | 12.01.25
